Nano Science and Technology Institute - NSTI  
Nano Science and Technology Institute   Home | Subscribe | Site Map  
  ABOUT | COURSES | EVENTS | PUBLICATIONS | LEADERSHIP | OUTREACH | NEWS | PRESS | JOBS | Nanotechnology Solutions
px
px fade_top
Publications
Nanotech 2008 CDROM
Nanotech 2007 CDROM
Nanotech 2006 CDROM
Nanotech 2005 CDROM
Nanotech 2004 CDROM
3 CDROM Special Offer
Nanotech 2008 Vol. 1
Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 3
Nanotech 2007 Vol. 1
Nanotech 2007 Vol. 2
Nanotech 2007 Vol. 3
Nanotech 2007 Vol. 4
Nanotech 2006 Vol. 1
Nanotech 2006 Vol. 2
Nanotech 2006 Vol. 3
Nanotech 2005 Vol. 1
Nanotech 2005 Vol. 2
Nanotech 2005 Vol. 3
WCM 2005
Nanotech 2004 Vol. 1
Nanotech 2004 Vol. 2
Nanotech 2004 Vol. 3
Nanotech 2003 Vol. 1
Nanotech 2003 Vol. 2
Nanotech 2003 Vol. 3
Nanotech 2002 Vol. 1
Nanotech 2002 Vol. 2
Nanotech 2001 Vol. 1
Nanotech 2001 Vol. 2
MSM 2000
MSM 99
MSM 98
Index of Authors
Index of Keywords
Index of Affiliations
Library Request Form
Shopping Cart
Order Form
 
Publications Publications
Nanotech 2005 Vol. 1
p
 
Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Volume 1
Nanotech 2005 Vol. 1
Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Volume 1
 
Chapter 1: Nanotechnology for Cancer
 

Photo-Enhanced Luminescence in Bio-conjugated Quantum Dots for Ovarian Cancer Biomarkers

Authors:M. Dybiec, N.E. Korsunska, P. Zhukov, S. Ostapenko, T. Sellers, A. Zajac and T. Zhukov
Affilation:University of South Florida, US
Pages:35 - 38
Keywords:quantum dots, labeling, ovarian cancer
Abstract:Ovarian cancer is the most lethal gynecologic malignancy. This largely reflects the fact that approximately 75% of cases are detected at advanced stages of disease, when cure is unlikely. In contrast, 5-year survival for patients with early stage ovarian cancer can exceed 90%. It is possible therefore that detecting a greater number of patients with early stage disease by improving screening modalities could significantly improve overall survival. To date, detection of the secreted tumor marker CA 125 is the only biomarker available for screening and therapeutic monitoring, however it has limited sensitivity (70%). A novel approach to increase the sensitivity and specificity of early detection of cancer is through the application of nanotechnology, where luminescent semiconductor quantum dots (QDs) are conjugated with biomolecules.
ISBN:0-9767985-0-6
Pages:844
Hardcopy:$165.00
 
Order:Mail/Fax Form
Special:3 CD Set — 15% off with Free Shipping
Up
nanoPRwire™
nanoPRwire
News Headlines
nano World news
 
 
 
 
px
© Nano Science and Technology Institute     About NSTI | Terms of Use | Privacy Policy | Contact